MRZM · Marizyme, Inc.

Marizyme, Inc., a Nevada corporation engaged in medical technology development, executed a general Assignment for the Benefit of Creditors on April 14, 2026, following Board authorization on April 9, 2026. This action signals acute liquidity distress, as the Company explicitly states it is unable to pay debts as they become due and seeks to maximize creditor recoveries through an orderly state-law liquidation process under Florida Statutes Chapter 727. Peter Hurwitz, the appointed Assignee based in New York, receives all non-exempt assets—including real property, inventory, equipment, accounts receivable, cash, and claims—detailed in Schedules A (creditors) and B (assets). The Assignee's duties include taking possession, liquidating with reasonable dispatch, covering administrative costs first, and distributing proceeds pro rata to creditors based on statutory priorities under § 727.114. This structure prioritizes creditor protection over continuation as a going concern, effectively winding down operations. For investors, this represents a cessation of business activities, with any surplus after full payments reverting to the Company, though unlikely given the insolvency admission. The notarized execution by CEO David Barthel underscores formal compliance, positioning this as the terminal event for Marizyme's current structure.